التفاصيل البيبلوغرافية
| العنوان: |
Efficacy and safety of proactive treatment with twice-weekly topical Cal/BD foam in patients with plaque psoriasis undergoing HPA-axis testing: a PSO-LONG subgroup analysis. |
| المؤلفون: |
Papp, Kim, Adamski, Zygmunt, Guenther, Lyn, Liljedahl, Monika, Miasik-Pogodzinska, Agnieszka, Szponar-Bojda, Anna, Lynde, Charles, Nutt, Terri, Mørch, Marie Holst, Tyring, Stephen, Werschler, William, Reich, Adam, Sadick, Neil, Turchin, Irina, Lacour, Jean-Philippe |
| المصدر: |
Journal of Dermatological Treatment; Jun2022, Vol. 33 Issue 4, p2297-2304, 8p |
| مصطلحات موضوعية: |
FOAM, BODY surface area, PSORIASIS, SUBGROUP analysis (Experimental design) |
| مستخلص: |
In PSO-LONG, long-term proactive management (PAM) of psoriasis with fixed-dose combination calcipotriol 50 µg/g and betamethasone dipropionate 0.5 mg/g (Cal/BD) aerosol foam was superior to conventional reactive management. This post-hoc analysis investigated long-term PAM with Cal/BD foam in PSO-LONG patients who could be more susceptible to corticosteroid-induced hypothalamic-pituitary-adrenal (HPA) axis suppression. Efficacy and safety of PAM with Cal/BD foam (twice-weekly) versus reactive management (twice-weekly vehicle foam), with once-daily rescue Cal/BD foam for four weeks following relapse, was assessed in the HPA subgroup (n = 66); patients had moderate-to-severe psoriasis (physician global assessment score ≥3; 10–30% body surface area affected). Primary endpoint was time to first relapse. PAM with Cal/BD foam was associated with longer median time to first relapse (111 versus 31 days), reduced risk of first relapse (hazard ratio: 0.49; p =.029), greater proportion of days in remission (17%; p =.001) and reduced rate of relapse (60% reduction; p <.001) than reactive management. Adverse events occurred in 37.5% (PAM) and 47.1% (reactive management) of patients, with no new safety signals. No clinically significant HPA-axis suppression was observed. Efficacy of PAM with Cal/BD foam is maintained in patients with moderate-to-severe psoriasis, with no new safety signals. [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Dermatological Treatment is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
